Skip to content

IMPEL PHARMACEUTICALS INC

CIK 0001445499

← back to feed
Revenue (TTM)
$19.06M
+1,794.0% YoY Q3 Nov 2023
Net Income (TTM)
−$82.34M
−38.9% YoY Q3 Nov 2023
EPS Diluted (TTM)
−$3.47
+13.7% YoY Q3 Nov 2023
Gross Margin
51.5%
Q3 Nov 2023
Operating Margin
-391.3%
Q3 Nov 2023
Net Margin
-432.0%
Q3 Nov 2023
Free Cash Flow (TTM)
−$70.39M
Q3 Nov 2023
Cash
$239K
Q3 Nov 2023
Total Debt
$0
Q3 Nov 2023
Shares Outstanding
23.9M sh
Q3 Nov 2023

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings